# Spironolactone for Pulmonary Arterial Hypertension

> **NCT01712620** · PHASE2 · RECRUITING · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 70 (estimated)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Spironolactone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01712620
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2014-01-10
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01712620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01712620, "Spironolactone for Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01712620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*